Statistical Considerations for Clinical Trials During COVID-19: Phase 1 Cancer Trials

Michael T. Tirgan; Qing Liu; Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Phase 1 Cancer Trials

Michael T. Tirgan, Qing Liu, Karl E. Peace

Biostatistics, Epidemiology & Environmental Health Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Oncology drug discovery and proper conduct of cancer clinical trials are essential to our battle against cancer. According to a 2015 Center for Disease Control and Prevention (CDC) report, the expected cancer cases and deaths in 2020 are 1.9 million and 630,000. While the world is fighting COV-19 pandemic, it is also important to be more creative than ever to continue anti-cancer drug development in a safe manner - without exposing cancer patients to unnecessary COVID-19 risks while maintaining the integrity of cancer clinical trials.

Original language	American English
Journal	LinkedIn
State	Published - Apr 20 2020

Disciplines

Biostatistics
Environmental Public Health
Epidemiology
Public Health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://www.linkedin.com/pulse/statistical-considerations-clinical-trials-during-phase-asa-fellow/?trackingId=LX53f4B%2FQGitQHxKw%2BqSwg%3D%3D

Cite this

@article{26b1747ca3984b2eb3a006f8c14cb433,

title = "Statistical Considerations for Clinical Trials During COVID-19: Phase 1 Cancer Trials",

abstract = " Oncology drug discovery and proper conduct of cancer clinical trials are essential to our battle against cancer. According to a 2015 Center for Disease Control and Prevention (CDC) report, the expected cancer cases and deaths in 2020 are 1.9 million and 630,000. While the world is fighting COV-19 pandemic, it is also important to be more creative than ever to continue anti-cancer drug development in a safe manner - without exposing cancer patients to unnecessary COVID-19 risks while maintaining the integrity of cancer clinical trials.",

author = "Tirgan, {Michael T.} and Qing Liu and Peace, {Karl E.}",

year = "2020",

month = apr,

day = "20",

language = "American English",

journal = "LinkedIn",

}

TY - JOUR

T1 - Statistical Considerations for Clinical Trials During COVID-19: Phase 1 Cancer Trials

AU - Tirgan, Michael T.

AU - Liu, Qing

AU - Peace, Karl E.

PY - 2020/4/20

Y1 - 2020/4/20

N2 - Oncology drug discovery and proper conduct of cancer clinical trials are essential to our battle against cancer. According to a 2015 Center for Disease Control and Prevention (CDC) report, the expected cancer cases and deaths in 2020 are 1.9 million and 630,000. While the world is fighting COV-19 pandemic, it is also important to be more creative than ever to continue anti-cancer drug development in a safe manner - without exposing cancer patients to unnecessary COVID-19 risks while maintaining the integrity of cancer clinical trials.

AB - Oncology drug discovery and proper conduct of cancer clinical trials are essential to our battle against cancer. According to a 2015 Center for Disease Control and Prevention (CDC) report, the expected cancer cases and deaths in 2020 are 1.9 million and 630,000. While the world is fighting COV-19 pandemic, it is also important to be more creative than ever to continue anti-cancer drug development in a safe manner - without exposing cancer patients to unnecessary COVID-19 risks while maintaining the integrity of cancer clinical trials.

UR - https://digitalcommons.georgiasouthern.edu/bee-facpubs/161

UR - https://www.linkedin.com/pulse/statistical-considerations-clinical-trials-during-phase-asa-fellow/?trackingId=LX53f4B%2FQGitQHxKw%2BqSwg%3D%3D

M3 - Article

JO - LinkedIn

JF - LinkedIn

ER -

Statistical Considerations for Clinical Trials During COVID-19: Phase 1 Cancer Trials

Abstract

Disciplines

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this